Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its H5 avian influenza mRNA vaccine mRNA‑1018 into Phase 3 testing. The grant follows earlier U.S. government contracts that were later canceled and includes a manufacturing commitment to reserve 20% of capacity for low‑ and middle‑income countries at affordable pricing if the vaccine is approved. CEPI’s support revives momentum for Moderna’s pandemic‑preparedness program amid renewed H5 outbreak concerns and underscores continued global interest in mRNA platforms for rapid vaccine response.